Insider Selling: Chimerix, Inc. (NASDAQ:CMRX) CEO Sells $33,312.40 in Stock

Chimerix, Inc. (NASDAQ:CMRX) CEO Michael T. Andriole sold 7,370 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total value of $33,312.40. Following the completion of the transaction, the chief executive officer now owns 609,603 shares of the company’s stock, valued at $2,755,405.56. This represents a 1.19 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Chimerix Price Performance

Shares of CMRX opened at $4.38 on Monday. Chimerix, Inc. has a one year low of $0.75 and a one year high of $4.65. The firm has a market capitalization of $393.94 million, a P/E ratio of -4.66 and a beta of 0.35. The business has a fifty day moving average of $3.53 and a 200 day moving average of $1.83.

Institutional Trading of Chimerix

Large investors have recently modified their holdings of the company. Stoneridge Investment Partners LLC grew its holdings in Chimerix by 22.5% during the fourth quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company’s stock valued at $154,000 after purchasing an additional 8,134 shares during the period. Bender Robert & Associates bought a new stake in Chimerix during the fourth quarter valued at about $37,000. Susquehanna Fundamental Investments LLC bought a new stake in Chimerix during the fourth quarter valued at about $59,000. Jane Street Group LLC bought a new stake in Chimerix during the fourth quarter valued at about $62,000. Finally, Diadema Partners LP bought a new stake in Chimerix during the fourth quarter valued at about $101,000. Institutional investors own 45.42% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of Chimerix in a research note on Monday, December 30th. Wedbush reaffirmed an “outperform” rating and issued a $6.00 price objective on shares of Chimerix in a report on Tuesday, December 10th.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.